

Repository of the Max Delbrück Center for Molecular Medicine (MDC)  
Berlin (Germany)  
<http://edoc.mdc-berlin.de/11132/>

## Forced Expression of LIM Homeodomain Transcription Factor 1b Enhances Differentiation of Mouse Embryonic Stem Cells into Serotonergic Neurons

---

*Virginie Dolmazon, Natalia Alenina, Suzy Markossian, Jimmy Mancip, Yvonne van de Vrede, Emeline Fontaine, Colette Dehay, Henry Kennedy, Michael Bader, Pierre Savatier, and Agnieszka Bernat*

This is a copy of an article published in the “Stem Cells and Development” © 2011 copyright Mary Ann Liebert, Inc.; “Stem Cells and Development” is available online at:  
<http://online.liebertpub.com>.

# Forced Expression of LIM Homeodomain Transcription Factor 1b Enhances Differentiation of Mouse Embryonic Stem Cells into Serotonergic Neurons

Virginie Dolmazon,<sup>1-3</sup> Natalia Alenina,<sup>4</sup> Suzy Markossian,<sup>1-3</sup> Jimmy Mancip,<sup>1-3</sup>  
Yvonne van de Vrede,<sup>1-3</sup> Emeline Fontaine,<sup>1-3</sup> Colette Dehay,<sup>1-3</sup> Henry Kennedy,<sup>1-3</sup>  
Michael Bader,<sup>4</sup> Pierre Savatier,<sup>1-3</sup> and Agnieszka Bernat<sup>1-3</sup>

The LIM homeodomain transcription factor 1b (*Lmx1b*) is a key factor in the specification of the serotonergic neurotransmitter phenotype. Here, we explored the capacity of *Lmx1b* to direct differentiation of mouse embryonic stem (mES) cells into serotonergic neurons. mES cells stably expressing human *Lmx1b* were generated by lentiviral vector infection. Clones expressing *Lmx1b* at a low level showed increased neurogenesis and elevated production of neurons expressing serotonin, serotonin transporter, tryptophan hydroxylase 2, and transcription factor *Pet1*, the landmarks of serotonergic differentiation. To explore the role of *Lmx1b* in the specification of the serotonin neurotransmission phenotype further, a conditional system making use of a floxed inducible vector targeted into the *ROSA26* locus and a hormone-dependent Cre recombinase was engineered. This novel strategy was tested with the reporter gene encoding human placental alkaline phosphatase, and demonstrated its capacity to drive transgene expression in *nestin*<sup>+</sup> neural progenitors (NPs) and in *Tuj1*<sup>+</sup> neurons. When it was applied to inducible expression of human *Lmx1b*, it resulted in elevated expression of serotonergic markers. Treatment of neural precursors with the floor plate signal Sonic hedgehog further enhanced differentiation of *Lmx1b*-overexpressing NPs into neurons expressing 5-HT, serotonin transporter, tryptophan hydroxylase 2, and *Pet1*, when compared with *Lmx1b*-nonexpressing progenitors. Together, our results demonstrate the capacity of *Lmx1b* to specify a serotonin neurotransmitter phenotype when overexpressed in mES cell-derived NPs.

## Introduction

**E**MBRYONIC STEM (ES) CELLS have the capacity to differentiate into a large variety of cell types in vitro, owing to their high self-renewal capacity and intrinsic pluripotentiality [1]. ES cells can be used to dissect the molecular mechanisms underlying in vitro differentiation into specialized cell types, such as serotonergic neurons. Several protocols to coax differentiation of mouse, rhesus, and human ES (hES) cells into neural progenitors (NPs) and then to direct differentiation of those progenitors into serotonergic neurons have been described [2–7]. These protocols make use of growth factors and cytokines known to regulate serotonergic differentiation in the mouse central nervous system. Implicit to this experimental paradigm, the developmental program employed by ES cells to differentiate into serotonergic neurons in vitro, largely, if not fully, recapitulates the developmental program executed during neurogenesis in the developing embryo.

Serotonergic (5-HT) neurons reveal a close ontogenetic relationship to midbrain dopaminergic (DA) neurons as both neuronal subtypes derived from ventral neuroepithelial progenitors located on either side of the midbrain–hindbrain boundary, starting at embryonic day 10.5 in the mouse [8–10]. According to the prevailing model, the development of both 5-HT depends critically on sonic hedgehog (Shh) synthesized by the floor plate, fibroblast growth factor 8 (FGF8) generated by the midbrain–hindbrain organizer, and FGF4 produced by the primitive streak [11,12]. NPs located more rostrally, thus away from the FGF4 signal, differentiate into DA neurons.

Several transcription factors are involved in serotonergic differentiation. *Mash1* and *Nkx2.2* expressed in NPs of the hindbrain activate the transcription factors *Gata2*, *Gata3*, LIM homeodomain transcription factor 1b (*Lmx1b*), and *Pet1* [13], which together define the serotonergic cell type by activating marker genes such as for tryptophan hydroxylase 2 (TPH2), aromatic amino acid decarboxylase, the serotonin

<sup>1</sup>INSERM U846, Bron, France.

<sup>2</sup>Stem Cell and Brain Institute, Bron, France.

<sup>3</sup>Université de Lyon, Lyon, France.

<sup>4</sup>Max Delbrück Center for Molecular Medicine, Berlin, Germany.

transporter (SERT), and the vesicular monoamine transporter 2 [14]. Both Gata2- and Gata3-deficient mice exhibit partial loss of serotonergic neurons [13,15]. In mice lacking Pet1, 70% of serotonergic progenitors fail to differentiate, whereas in the remaining Pet1-deficient neurons diminished expression of TPH and SERT was observed [16]. Lmx1b is crucially involved in the formation of the entire serotonin system in the hindbrain, because its deletion in mice leads to the absence of 5-HT neurons in the brain [17–19]. It is expressed in developing 5-HT neurons together with Pet1 starting around E11 in the rostral cluster of serotonergic differentiation and 1 day after in the caudal one, consistent with the delayed appearance of serotonergic cells in the latter region [18]. Lmx1b ablation does not affect expression of Nkx2.2, Gata3, and Shh, putting these factors upstream of Lmx1b [17,18]. Together with Nkx2.2, GATA3, and Pet1, Lmx1b can induce ectopically the development of serotonergic neurons in the chick neural tube, a function that Nkx2.2 and Pet1 cannot support on their own [18,20]. Lmx1b is also involved in the maintenance of the DA neurotransmitter phenotype in collaboration with the orphan nuclear receptor Nurr1 [21]. Therefore, Lmx1b plays a central role in the differentiation of 5-HT neurons, and an ancillary role in the differentiation of midbrain DA neurons.

Differentiation of mouse ES (mES) cells into serotonergic neurons is highly efficient. In a pioneer study, sequential exposure of mES cell-derived nestin<sup>+</sup> NPs to FGF4 and then to FGF8 and Shh led to a 2.5-fold increase in the number of serotonergic neurons resulting in ~25% of the neurons being 5-HT positive [22]. Using stromal cell cultures to induce differentiation of mES cells and adding the same combination of factors, Barberi et al. were able to define conditions in which the mouse ES cells were differentiated into 60% 5-HT expressing neurons [3]. Similar results were obtained with hES cells. Under nonoptimized differentiation conditions, <1% of the hES cell-derived neurons obtained are serotonin positive [23,24]. Addition of factors that included Shh, FGF4, FGF8, glial-derived neurotrophic factor, and brain-derived neurotrophic factor increased the number of 5-HT expressing cells to 25% of the  $\beta$ -III-tubulin-positive cell population. In a recent study, 40% of NPs could be converted to serotonergic neurons expressing serotonin, Tph2, and the transcription factors Mash1, Pet1, and Lmx1b [6].

Herein, we asked if overexpression of Lmx1b expression is sufficient to drive differentiation of mES cell-derived NPs to the serotonergic neuron pathway. We developed 2 experimental approaches, the first one based on lentiviral vector-based stable expression and the second one on conditional expression induced by 4'hydroxytamoxifen (4'OHT) in NPs. In both experimental systems, Lmx1b was found to promote serotonergic differentiation, either alone or in cooperation with dorsoventralizing factors.

## Materials and Methods

### Plasmid construction

To engineer *pR4SA-EFS-CreER<sup>T2</sup>-W*, the *Cre-ER<sup>T2</sup>* coding sequence from *pCre-ER<sup>T2</sup>* [25] was subcloned between the *EcoRV* and *BamHI* sites of plasmid *pR4SA-EFS-GFP-W* [26].

To engineer *p2K7-HAhLmx1b*, the human *Lmx1b* cDNA from *pcDNA3.1hLmx1b* (a kind gift from S. Dreyer) was first HA tagged at its N-terminus by polymerase chain reaction

(PCR) amplification. It was subsequently subcloned between *BamHI* and *EcoRV* sites in plasmid *pGAE-CAG-eGFP-WPRE* [27]. In a second step, the CAG promoter (CMV early enhancer/chicken  $\beta$ -actin) from *pGAE-CAG-eGFP-WPRE* was cloned into *pDONRP4-P1R* (Invitrogen), and the *HAhLmx1b* cDNA from *pGAE-CAG-HAhLmx1b-WPRE* was cloned into *pDONR221* (Invitrogen), both using Gateway BP clonase enzyme mix (Invitrogen). The resulting 2 entry vectors were then recombined into *2K7neo* lentivector (kind gift of D. Suter) using Gateway LR plus clonase enzyme mix (Invitrogen) [28].

To engineer *pIGTE2-R26-hPLAP*, a 48-mer oligonucleotide containing a *PacI* site (5'-atTTtaattaagaagtctctattcttagaaagtataggaacttcgat-3') and a 54-mer oligonucleotide containing an *AscI* site (5'-ctagagctagcgaagttctattctcaaatagtaggaactt cggcgccca-3') were first subcloned into the *SspI* and *AscI* sites of plasmid *pIGTE2-hAP* [29], respectively. The resulting plasmid was digested with *PacI* and *AscI*, and the 3.8 kb fragment was subcloned between *PacI* and *AscI* in *pRosa26PA* [30] to generate *pIGTE2-R26-hPLAP*. To engineer *pIGTE2-R26-hLmx1b*, a 1.2 kb *NheI/XbaI* fragment encompassing human *Lmx1b* cDNA was prepared from *pcDNA3.1hLmx1b* (a kind gift from S. Dreyer), and subcloned in *pCMV-lres-pA* to generate *pCMVhLmx1b*. The *pCMVhLmx1b* plasmid was next digested with *NheI*, and the resulting 2.9-kb insert was subcloned between both *NheI* sites into *pIGTE2* to generate *pIGTE2-hLmx1b*. *PacI* and *AscI* sites were added as described above for *pIGTE2-hAP*, and the resulting *PacI/AscI* fragment was subcloned between *PacI* and *AscI* in *pRosa26PA* to generate *pIGTE2-R26-hLmx1b*.

### mES cell culture and electroporation

mES cells (CGR8) were maintained on 0.1% gelatinized (Sigma) tissue culture dishes in Glasgow's modified Eagle's medium supplemented with 10% fetal calf serum (Biowest), 1,000 U/mL of leukemia inhibitory factor (LIF), 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/mL penicillin–100  $\mu$ g/mL streptomycin, and 100  $\mu$ M  $\beta$ -mercaptoethanol (all from Invitrogen). About  $5 \times 10^6$  CGR8 cells were electroporated at 0.26 kV and 960  $\mu$ F with 40  $\mu$ g of *pIGTE2-R26-hPLAP* or *pIGTE2-R26-hLmx1b* plasmid linearized with *SwaI*. Stably transfected cells were selected with 80  $\mu$ g/mL hygromycin B (Roche Applied Science) for 8 days. Drug-resistant colonies were expanded before analysis and frozen.

### Neuronal differentiation

Neural induction and neuronal differentiation were performed by means of coculture of mES cells with the MS5 stromal cell line as previously described [3]. In brief, mES cells were seeded at a density of 10–50 cells/cm<sup>2</sup> on the layer of mitomycin-inactivated MS5 cells, and maintained in knockout Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 15% (vol./vol.) knockout serum replacement, 2 mM L-glutamine, and 10  $\mu$ M  $\beta$ -mercaptoethanol (all from Invitrogen), for 8 days to allow neural induction. Neuroepithelial colonies were harvested with a fire-pulled Pasteur pipette, dissociated by gentle trypsinization, and replated on Matrigel (BD Biosciences)-coated dishes in Neurobasal medium without phenol red, supplemented with 200 mM glutamine, 5  $\mu$ g/mL bovine fibronectin, N2 and B27

supplement (all from Invitrogen), and 20 ng/mL FGF2 (AbCys). FGF4 (100 ng/mL), FGF8 (100 ng/mL), and SHH (200 ng/mL) (R&D Systems) were added to the culture medium at times indicated. To induce neuronal differentiation, FGF2 was withdrawn from the medium at day 11–12, and replaced with 20 ng/mL brain-derived neurotrophic factor (R&D Systems), 200  $\mu$ M ascorbic acid (Sigma), and 20 ng/mL neurotrophin 3 (R&D Systems). Final differentiation was allowed for 5–6 days. 4'OHT (Calbiochem) was added to the culture medium for the time and concentration indicated.

Neural differentiation was also induced by the formation of embryoid bodies (EBs) as previously described [5,31,32]. In brief,  $6 \times 10^6$  ES cells were cultured in suspension in 10 mL of the medium (Glasgow's modified Eagle's medium supplemented with 10% vol./vol. knockout serum replacement, 2 mM L-glutamine, 1 mM sodium pyruvate, and  $1 \times$  non essential amino acids (NEAA); all from Invitrogen) in a 10-cm dish. After 8 days, EBs were dissociated and replated at a density of  $2.5 \times 10^4$  cells/cm<sup>2</sup> on poly-D-lysine/laminin (Sigma) in the N2B27 medium (Invitrogen). After replating, neural precursor cells were enriched for 2 days by the addition of 10 ng/mL FGF2 (R&D Systems). Withdrawal of FGF2 in the N2B27 medium resulted in production of postmitotic neurons (from day 11 to 18).

#### *Production of lentiviral vectors and infection*

The method for simian immunodeficiency virus (SIV)-based vector production in 293T cells is fully described elsewhere [26,33]. In brief, 293T cells were transfected by the calcium phosphate method with a mixture of DNA containing *pGRev* plasmid encoding the vesicular stomatitis virus glycoprotein envelope, *pSIV3+* plasmid encoding the gag, pol, tat, and rev proteins, and *pR4SA-EFS-CreER<sup>T2</sup>-W*. The next day, cells were refed with the fresh medium and further cultured for 48 h. The supernatant was then collected, cleared by centrifugation (3,000 rpm and 15 min), and passed through a 0.8- $\mu$ m filter to remove cell and debris. For infection,  $10^4$  freshly trypsinized mES cells were resuspended into 1 mL of 293T cell supernatant producing the desired virus in the presence of 8  $\mu$ g/mL sequabrene (Sigma), plated on a 2-cm-diameter dish, and cultured for 48 h before cloning by limiting dilution. The production of lentiviral particles from plasmid *p2K7neo-HAHLmx1b* was performed as described [28,34].

#### *DNA and RNA extraction, Southern blot, and real-time PCR*

For genomic DNA extraction, cells were lysed in 10 mM Tris-HCl (pH 8), 1 mM ethylenediaminetetraacetic acid (pH 8), 100 mM NaCl, and 0.5% sodium dodecyl sulfate. The resulting lysate was treated with 0.2 mg/mL RNase for 1 h at 37°C, followed by proteinase K treatment (0.2 mg/mL, 55°C, overnight). DNA was separated from proteins by phenol-chloroform extraction, precipitated with isopropanol, and resuspended in 1 mM Tris-HCl and 0.1 mM ethylenediaminetetraacetic acid (pH 8). Ten micrograms of *EcoRV*-digested genomic DNA was separated on a 0.8% agarose gel, transferred to a nylon membrane (Hybond-N<sup>+</sup>; Amersham), and hybridized with <sup>32</sup>P-labeled (Ready-to-Go Labeling Kit; Amersham) probe. RNA was extracted using


RNAeasy kit (Qiagen) with on-column DNase (Qiagen) digestion, and reverse transcription carried out with MuMLV-RT (Promega) according to the manufacturer's recommendations. Quantitative PCR was performed using the LightCycler™ 1.5 system and the LightCycler Fast Start DNA Master SYBR Green I kit (Roche Applied Science) according to the manufacturer's instructions. Reactions were carried out in a total volume of 10  $\mu$ L, comprising 0.4  $\mu$ M of each primer, 0.75  $\mu$ L SYBR Green, 2.5  $\mu$ L of diluted cDNA, and 2–4 mM MgCl<sub>2</sub> according to primers. Amplification and online monitoring was performed using the LightCycler 1.5 system. After 40 amplification cycles, melt-curve analyses were performed to verify that only the desired PCR product had been amplified. PCR efficiency of both the target and reference genes was calculated from the derived slopes of standard curves by LightCycler software (Roche Molecular Biochemicals; LightCycler Software, version 3.0). These PCR efficiency values were used to calculate the relative quantification values for calibrator-normalized target gene expression by LightCycler relative quantification software (version 1.0). All normalizations were carried out with  $\beta$ -actin. Semiquantitative PCR was performed using Euroblue Taq polymerase according to supplier (Eurobio) instructions. Sequences of primers are given in Supplementary Table S1 (available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)).

#### *Histochemical detection and immunolabeling*

Histochemical analysis for hAP expression in cultured cells and quantification of hAP activity in protein lysates were carried out as described previously [29]. For immunolabeling, cells were washed in phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde in PBS at room temperature for 30 min. After the rinse with PBS, cells were permeabilized in 0.2% Triton X-100 in PBS for 15 min. Nonspecific binding was blocked with nonimmune normal goat serum (Zymed) for 30 min at room temperature. Primary antibodies were applied in 1% normal goat serum (Invitrogen) in PBS. The following primary antibodies were used: human placental alkaline phosphatase (hPLAP; Sigma),  $\beta$ -III-tubulin (Chemicon and Covance), PSA-NCAM (Chemicon), and 5-HT (Sigma). After incubation at 37°C for 1 h, followed by several rinses in PBS, appropriate fluorochrome-conjugated secondary antibodies were added (Molecular Probes). The cells were incubated at 37°C for 30 min and, after extensive washes in PBS, mounted on glass microscope slides using Vectashield HARD mounting medium (Vector Labs, Inc.) containing DAPI for DNA counterstaining.

#### *Enzyme-linked immunosorbent assay*

To evaluate the 5-HT level in postmitotic neuronal culture, cells were lysed in PBS containing 0.1% ascorbic acid (Sigma) by repeated freezing (–80°C) and thawing. The extracts were sonicated and separated from debris by centrifugation (30 min 14,000 rpm). The protein concentration was estimated using Coomassie blue staining. Enzymatic immunoassay for 5-HT was performed with nano-detection kit Serotonin EIA BA 10-0900 (Labor Diagnostika Nord) following manufacturer's instructions. Serotonin concentration measured with the EIA kit was normalized to total protein content.




**FIG. 1.** Neuronal differentiation of mouse embryonic stem (mES) cells overexpressing human LIM homeodomain transcription factor 1b (*hLmx1b*). **(A)** Real-time polymerase chain reaction (PCR) analysis of *hLmx1b* mRNA level in mES cell clones (L1–L12) infected with *p2K7-HA. **(B)** Neuroepithelial colonies at day 8 of differentiation formed by clones L1, L11, and control cells, MS5 protocol. Scale bar: 100 μm. **(C)** Surface of neuroepithelial colonies at day 8 of differentiation in clones L1 and L11, and in control cells (MS5 protocol). **(D)** Counting of neural progenitors (NPs) at day 12 of differentiation obtained with clones L1 and L11, and control cells (MS5 protocol). **(E)** Real-time PCR analysis of *Map2ab* expression levels at day 15 of differentiation with clones L1 and L2, and with control cells (MS5 protocol) after normalization with p-actin. **(F)** Real-time PCR analysis of *Tuj1* expression levels at day 17 of differentiation in clones L1 and L3, and with control cells (embryoid body protocol). **(G)** Semiquantitative reverse transcriptase (RT)-PCR analysis of *HA-hLmx1b* expression in clones L1 and L2, and in control cells, at day 0 (mES cells), day 8 (neuroepithelial colonies), and day 15 (postmitotic neurons) (MS5 protocol). **(C–F)** Histograms represent means and standard errors calculated in 3 replicates. Statistical significance was determined with the unpaired two-sided *t*-test (\**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001). **(A, E, F)** Expression levels are normalized to the level measured in e12.5 total brain.*

## Results


### Neuronal differentiation of mES cells overexpressing *Lmx1b*

CGR8 mES cells were infected with *p2K7-HA, a lentiviral vector expressing human *Lmx1b* cDNA driven by the ubiquitous CAG promoter. Clones expressing *hLmx1b* at low (L1, L2, L3, L4, L9, and L10), intermediate (L5, L6, L7, L8, and L12), and high (L11) levels were isolated (Fig. 1A). They were cultured onto MS5 stromal cells for 8 days to form neuroepithelial colonies, which were subsequently dissociated and replated on Matrigel-coated dishes in the presence of FGF2 to amplify a morphologically homogenous population of NPs, which is uniformly immunoreactive for NP-specific antigens such as nestin and PSA-NCAM [3] (hereafter called*

MS5 protocol). NPs were induced to differentiate into Tuj1<sup>+</sup> neurons by withdrawal of FGF2 for 4–6 days (data not shown). We observed that *hLmx1b* expression dramatically influenced both the yield of neuroepithelial colonies at day 8 and the yield of NPs after colony dissociation and replating at day 12. More specifically, clone L11 (high expressor) produced significantly smaller neuroepithelial colonies in comparison either with control mES cells (56% reduction in size) or with low expressor L1 (43% reduction) (Fig. 1B, C). Of note, the number of neuroepithelial colonies did not vary significantly between clones, indicating that *hLmx1b* expression did not interfere with clonogenicity and survival of dissociated mES cells in these culture conditions (data not shown). We thus hypothesized that *hLmx1b* overexpression altered proliferation and/or survival of transient amplifying NPs. This hypothesis was confirmed after counting NPs upon dissociation of neu-



**FIG. 2.** Serotonergic and dopaminergic differentiation of mES cells overexpressing *hLmx1b* (embryoid body protocol). Real-time PCR analysis of tryptophan hydroxylase 2 (*Tph2*), serotonin transporter (*SERT*) and *Pet1* (**A**), tyrosine hydroxylase (*TH*), *Lmx1a*, and *Isl1* (**C**), mRNA levels in clones L1 and L3, and in control cells, at day 17 of differentiation. Expression levels are normalized to *Tuj1* and then to the level measured in e12.5 total brain. (**B**) Double immunofluorescence analysis of *Tuj1* (green)- and 5-HT (red)-positive neurons, performed at differentiation day 15 of clones L1 and L3, and control cells. Nuclei are labeled with DAPI. Scale bar: 250  $\mu$ m. (**D**) Quantification of 5-HT in cell extracts of neuron cultures at day 17 of differentiation by serotonin enzyme-linked immunosorbent assay. (A, C, D) \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ .



**FIG. 3.** Generation of an inducible expression vector and ES cell line for conditional gene expression. (**A**) Schematic representation of the *ROSA26* locus after targeted integration of *pIGTE2-R26-hPLAP* plasmid before and after Cre-mediated excision of the *hygro-polyA* cassette. The position of the *SacII-PaclI* probe used for Southern blot analysis is indicated. *Hygro<sup>R</sup>*, gene conferring resistance to hygromycin B; PolyA, transcription termination and polyadenylation signals. (**B**) Southern blot analysis of the *ROSA26* locus after digestion with *EcoRV* and hybridization with a radioactive probe. (**C**) Human placental alkaline phosphatase (hPLAP) activity measured in 3 independent undifferentiated WTC15-R26-hPLAP clones before and after treatment with 100 nM 4'-hydroxytamoxifen (4'OHT) for 48 h. (**D**) Southern blot analysis of the *ROSA26* locus in WTC15-R26-hPLAP-7 clone after digestion with *EcoRV*, before and after treatment with 4'OHT (100 nM, 48 h). (**E**) Immunofluorescence analysis of hPLAP expression in NPs and postmitotic neurons before and after treatment with 4'OHT (100 nM, 48 h). Low panels show DAPI staining of DNA. Scale bar: 100  $\mu$ m.

roepithelial colonies at day 8, and subsequent culture for 4 days. Clone L11 (high expressor) exhibited a 50% reduction in the yield of nestin<sup>+</sup> NPs at day 12 compared with wild-type ES cells (Fig. 1D). Moreover, after withdrawal of FGF2, most L11-derived NPs failed to differentiate into mature neurons and degenerated (data not shown). In sharp contrast, clone L1 (low expressor) produced a 63% increase in nestin<sup>+</sup> NP number at day 12 (Fig. 1D) and, at day 15 (ie, 3 days after mitogen withdrawal), a 12-fold increase in pan-neuronal marker Map2ab expression. Comparable results were obtained with the low expressor L2 (Fig. 1E).

Similar data were obtained after neuronal differentiation induced by formation of EBs for 8 days, followed by replating for 2 days in the presence of FGF2, and subsequent mitogen withdrawal for 7 days (EB protocol). Compared with control cells, the low expressors L1 and L3 showed a 2.7- and 4-fold increase in pan-neuronal marker *Tuj1* expression, respectively (Fig. 1F). Of note, *hLmx1b* was expressed at constant levels throughout differentiation (Fig. 1G). Together, these results suggest that moderate overexpression of *Lmx1b* significantly increases the yield of neural/neuronal differentiation of mES cells.

### ES cells overexpressing *Lmx1b* show preferential differentiation toward serotonergic lineage in vitro

We next wanted to determine if *Lmx1b* overexpression influences differentiation of NPs into serotonergic, DA, and motoneurons. The low expressors L1 and L3 were used in this study as they both exhibited vastly elevated neuronal differentiation compared to high expressors. Expression of serotonergic-, DA-, and motoneuron-specific markers, after differentiation induced by EB formation, was measured by real-time PCR. Since both L1 and L3 clones showed differences in the yield of neuronal differentiation compared with control cells (see Fig. 1), the expression level of each marker was normalized to *Tuj1* (in addition to  $\beta$ -actin) to eliminate the bias resulting from overproduction of neurons by *hLmx1b*-expressing clones. E12.5 *dpc* brain extract was used as a reference throughout these experiments. Clones L1 and L3 exhibited increased expression of serotonergic markers, 9- and 3-fold for brain-specific serotonin producing enzyme *Tph2*, 7.7- and 2.5-fold for serotonin transporter (*SERT*), and 2.2-fold for serotonergic neuron-specific transcription factor *Pet1* (only L1) (Fig. 2A). Of note, a slight increase in DA markers tyrosine hydroxylase (*TH*) and *Lmx1a* was also evidenced, whereas expression of *Isl1*, a marker of motoneuron differentiation, was significantly decreased (Fig. 2B). The enrichment in serotonergic neurons at day 17 of differentiation in *Lmx1b*-overexpressing clones was confirmed by immunostaining against serotonin (Fig. 2C). Quantification of serotonin level by enzymatic immunoassay showed a 20-fold increase in 5-HT content in both L1 and L3 clones compared with control cells (Fig. 2D). These results indicate that neural precursors overexpressing *hLmx1b* at a low level show increased propensity for differentiation into 5-HT neurons.

### Generation of an inducible expression vector and ES cells suitable for conditional gene expression in NPs and postmitotic neurons

Since *Lmx1b* expression appeared detrimental to neural differentiation when overexpressed at high levels in mES

cells, we generated an inducible expression system to drive conditional expression of *hLmx1b* in the NP population. To this aim, we made use of a hormone-dependant Cre-ER<sup>T2</sup> recombinase and of an expression vector in which transgene transcription is blocked by 3 floxed transcription termination signals (Fig. 3A). This system displays 2 significant improvements with respect to our previously published system [29]: (1) the Cre-ER<sup>T2</sup> recombinase is expressed from a lentiviral vector in which the Cre-ER<sup>T2</sup> coding sequence is driven by the ubiquitously active truncated version of the EF1 $\alpha$  promoter [26]; (2) the expression vector contains 7 kb of genomic sequences that allow targeted integration into the *ROSA26* locus and subsequent transgene expression under the ubiquitously active regulatory elements of *ROSA26* [30]. A mES cell line expressing Cre-ER<sup>T2</sup> was produced by infection with pR4SA-EFS-CreER<sup>T2</sup>-W. This line, hereafter called WTC15, expresses CreER<sup>T2</sup> at high level in ES cells and in their differentiated derivatives (data not shown). Next, an inducible vector called *pIGTE2-R26-hPLAP* that harbors *hPLAP*, the gene encoding hPLAP, was introduced by electroporation into WTC15 cells. Ten individual hygromycin-resistant clones were analyzed, of which 3 displayed homologous recombination into the *ROSA26* locus (Fig. 3B). All 3 clones showed a 10- to 14-fold increase in hPLAP activity upon treatment with 4'OHT (100 nM, 48 h) (Fig. 3C). One of them, hereafter called WTC-hPLAP-7, was selected for further analysis. Treatment with 4'OHT resulted in excision of the *hygro-polyA* cassette (Fig. 3D). Immunofluorescence staining showed hPLAP expression in most cells after treatment with 100 nM 4'OHT for 48 h (Fig. 3E). Virtually, no hPLAP-positive cells could be detected in the untreated cell population, indicating that transgene expression was repressed completely in the absence of hormone.

WTC-hPLAP-7 cells were induced to differentiate into neuroepithelial colonies by means of coculture with MS5 stromal cells for 8 days, followed by amplification of the NP population by FGF2 for 3 days. To assess transgene induction in the neuroepithelial colonies, day 5 cultures were treated with 100 nM 4'OHT for 48 h. Expression of hPLAP was subsequently observed in >95% of the neuroepithelial colonies (Fig. 4A, panels b, c). Day 11 NPs, derived from neuroepithelial colonies in which expression of the transgene was induced at day 5, expressed hPLAP in virtually all cells (Fig. 4A, panels e, f). Most neurons generated at day 17 also expressed it (Fig. 4A, panels h, i). Analysis of *hPLAP* mRNA level by real-time PCR showed a 49-fold increase in day 11 NPs and a 9-fold increase in postmitotic neurons after induction with 4'OHT at the ES cell stage (day 0). When induction was performed at the neuroepithelial colony stage (day 5), a 51-fold increase in day 11 NPs and a 22-fold increase in postmitotic neurons were observed (Fig. 4B). Together, these results show that once induced, either in the undifferentiated state or during neural differentiation, hPLAP expression level is maintained throughout neuronal differentiation.

### Inducible expression of *Lmx1b* in ES-derived NPs stimulates neuronal production

A mES cell line conditionally expressing *hLmx1b* was engineered by electroporating *pIGTE2-R26-hLmx1b* plasmid into WTC15 mES cells. After selection, 9 hygromycin-


resistant clone in 12 displayed targeted integration into the *ROSA26* locus (Fig. 5A, B). Two homologous recombinant clones were tested, showing excision of the transcription termination cassette after 4'OHT treatment (100 nM, 48 h) (Fig. 5C). Clone 6, hereafter called WTC-hLmx1b-6, was chosen for all subsequent experiments. Real-time PCR analysis of *hLmx1b* expression in WTC-hLmx1b-6 showed a 55-fold increase in mRNA level upon 4'OHT induction at the ES cell stage (day 0), and a 9- and 14-fold increase in postmitotic neurons after induction at day 0 and at the neuroepithelial colony stage (day 5), respectively (Fig. 5D). Of note, *hLmx1b* expression levels in neurons produced from WTC-hLmx1b-6 ES cells after induction at day 5 were similar to expression levels measured in *hLmx1b*-stably expressing clones L1 and L2 (Fig. 5E). We also confirmed that the induction of *hLmx1b* expression in WTC-hLmx1b-6 ES cell-derived NPs increased Map2ab expression at day 18 (Fig. 5F), as it was observed with *hLmx1b*-stable clones L1, L2, and L3 (see Fig. 1E, F).

#### Inducible expression of *Lmx1b* cooperates with *Shh*, *FGF4*, and *FGF8* to induce serotonergic differentiation

We next asked whether the induction of *hLmx1b* expression in NPs promotes expression of serotonergic markers. Expression of *hLmx1b* was induced in the neuroepithelial colonies. After amplification in the presence of basic FGF, NPs were induced to differentiate into postmitotic neurons by mitogen withdrawal and the expression of serotonergic

markers analyzed by real-time PCR. mRNA levels measured in the WTC-hLmx1b-6-derived neurons were normalized: first, to pan-neuronal *Map2ab* marker level to eliminate variations in the yield of neuronal differentiation; second, to mRNA levels measured in the WTC-hPLAP-7-derived neurons to eliminate nonspecific effects of 4'OHT. We then observed a 1.4-, 1.6-, and 2.5-fold increase of *Pet1*, *Tph2*, and *SERT* mRNA levels, respectively (Fig. 6A).

Neuroepithelial colonies and amplifying NPs derived from both WTC-hPLAP-7 and WTC-hLmx1b-6 were exposed, either to Shh alone or to combinations of Shh and FGF4 (day 5–8) followed by Shh and FGF8 (day 8–12). This latter condition was described to promote serotonergic differentiation [3,6]. Expression of *hLmx1b* and *hPLAP* transgenes was induced by 4'OHT in the developing neuroepithelial colonies at day 5. In the presence of Shh, induction of *hLmx1b* expression—when it was compared to induction of *hPLAP*—resulted in a 10-, 30-, and 55-fold increase in *Pet1*, *Tph2*, and *SERT* expression levels in postmitotic neurons at day 18, respectively (Fig. 6B). Treatment with Shh and FGF4, followed by Shh and FGF8, did not further increase expression of *Tph2* (31-fold) and *SERT* (57-fold), and moderately increased expression of *Pet1* (16-fold) (Fig. 6C). Treatment with Shh combined with induced expression of *hLmx1b* also increased expression of DA markers, *En* (2.8-fold), *TH* (18.5-fold), and *Nurr1* (6.6-fold), when compared with expression levels in Shh-treated control cells (Fig. 6D). Further, addition of FGF4 and FGF8 to the differentiation cocktail reduced expression of *TH* and *Nurr1* by



**FIG. 4.** Conditional expression of hAP in neuroepithelial colonies, NPs, and postmitotic neurons. **(A)** Immunohistochemical analysis of hAP expression in neuroepithelial colonies at day 8 (**b, c**), in NPs at day 11 (**e, f**), and in neurons at day 18, following induction with 4'OHT (100 nM, 48 h), either in undifferentiated mES cells (**b, e, h**) or in neuroepithelial colonies at day 5 (**c, f, i**). *Left panels* show unstained neuroepithelial colonies (**a**), NPs after immunolabeling for PSA-NCAM (green) (**d**), and neurons after immunolabeling for Tuj1 (green) (**g**). DNA is counterstained with DAPI. Scale bar: 100  $\mu$ m. **(B)** Real-time PCR analysis of *hPLAP* expression in ES cells after induction at day 0, in day 11 NPs after induction both at day 0 and at day 5, and in day 17 neurons after induction both at day 0 and at day 5. Expression levels are normalized to the level measured in mES cells before induction. (\*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ).



2-fold in comparison with Shh alone (Fig. 6E), which is likely to reflect the capacity of FGF4 to inhibit DA differentiation [11].


Taken together, these results show that enforced expression of Lmx1b, combined with Shh, robustly stimulates expression of serotonergic markers in the differentiating NPs derived from mES cells.

## Discussion


The focus of this study was to demonstrate the role of Lmx1b in promoting differentiation of mES cell-derived NPs into serotonergic neurons. Lmx1b is essential to the development of the entire serotonergic system [17–19], as well as to the maintenance of the DA neurotransmitter phenotype in the mouse [21]. We thus asked if overexpression of Lmx1b

in mES cells is sufficient to specify serotonergic and DA phenotypes.

Forced expression of a transgene that drives differentiation often results in inability to form undifferentiated mES colonies and consequent recovery only of low expressing or deviant cells. We successfully generated mES cell lines that express hLmx1b ectopically, but only the lines expressing it at low level retained the capacity to differentiate into neural precursors harboring the growth characteristics of control cells. In contrast, mES cells expressing Lmx1b at high levels exhibited reduced capacity to form NPs, and those progenitors to differentiate into postmitotic neurons. Failure to differentiate could result either from the detrimental effect of Lmx1b when overexpressed at elevated levels, or from the selection of mutant mES cells that resisted to the differentiation-promoting effect of Lmx1b. To overcome this difficulty,



**FIG. 5.** Conditional expression of *hLmx1b* in neurons. **(A)** Schematic representation of the *ROSA26* locus after targeted integration of *pIGTE2-R26-hLmx1b* plasmid, before and after Cre-mediated excision of the *hygro-polyA* cassette. The position of the *SacII-PacI* probe used for Southern blot analysis is indicated. *Hygro<sup>R</sup>*, gene conferring resistance to hygromycin B; PolyA, transcription termination and polyadenylation signals. **(B)** Southern blot analysis of the *ROSA26* locus after digestion with *EcoRV* and hybridization with a radioactive probe. **(C)** Southern blot analysis of the *ROSA26* locus in WTC15-R26-hLmx1b-6 clone after digestion with *EcoRV*, before and after treatment with 4'OHT (100 nM, 48 h). **(D)** Real-time PCR analysis of *hLmx1b* expression in neurons derived from WTC-Lmx1b-6 clone after induction with 4'OHT either at day 0 (undifferentiated ES cells) or at day 5 (neuroepithelial colonies). **(E)** Real-time PCR analysis of *hLmx1b* expression in neurons derived from WTC-Lmx1b-6 clone (after induction with 4'OHT at day 5) and in neurons derived from hLmx1b-stably expressing clones L1 and L2. **(F)** Real-time PCR analysis of *Map2ab* expression in neurons derived from WTC-hPLAP-7 and WTC-hLmx1b-6 clone, after induction with 4'OHT at day 5. (E, F) Expression levels are normalized to the level measured in e12.5 total brain. (D, E, F) \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ .



**FIG. 6.** Inducible expression of hLmx1b in ES-derived NPs increases expression of serotonergic markers. (A–C) Real-time PCR analysis of *Pet1*, *Tph2*, and *SERT* mRNA levels in day 18 neurons derived from WTC-HLmx1b-6 clone after induction with 4'OHT at day 5 (neuroepithelial colonies), in the absence of dorsoventralizing factors (A) or in the presence of sonic hedgehog (Shh) (B) or in the presence of Shh, fibroblast growth factor 4 (FGF4), and FGF8 (C). (D, E) Real-time PCR analysis of *En*, *TH*, and *Nurr1* mRNA levels in day 18 neurons derived from WTC-HLmx1b-6 clone after induction with 4'OHT at day 5 (neuroepithelial colonies), either in the absence of dorsoventralizing factors (D) or in the presence of Shh, FGF4, and FGF8 (E). (A–E) Expression levels are normalized to the level measured in e12.5 total brain. (A–E) \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ .

we have engineered an inducible gene expression system that makes possible to overexpress differentiation-promoting genes in mES cell-derived NPs and to maintain their expression in differentiating neurons. Activation of *hLmx1b* in mES cell-derived NPs and its subsequent expression in postmitotic neurons, as revealed by the *hPLAP* reporter gene, reflect the expression pattern of *Lmx1b* in the mouse, starting in NPs of the hindbrain and being maintained in mature 5-HT neurons [17].

In both stably induced and 4'OHT-induced *Lmx1b* expressing mES cells, we observed that *Lmx1b* increases expression *Tph2*, *SERT*, and *Pet1*, the landmarks of serotonergic neurotransmitter phenotype. The effect of *Lmx1b* was observed using 2 different differentiation protocols, the first one based on coculture of ES cells with a stromal feeder cell line [3] and the second one based on EB formation [5], both of them including selection and amplification of nestin<sup>+</sup> NPs. These results indicate that *Lmx1b* expression is rate limiting for specifying the 5-HT phenotype, in accordance with the genetic data in the mouse [17–19]. The inductive effect of *Lmx1b* on serotonergic differentiation is strongly enhanced

when NPs are treated with the floor plate signal Shh. This result can be explained by the capacity of Shh to activate expression of ancillary factors acting in concert with *Lmx1b* to promote serotonergic differentiation. Indeed, the specification of serotonergic neurons requires a Shh-regulated cascade of transcription factors to generate 5-HT neurons in vivo. Shh-activated homeodomain proteins Nkx2.2 and Nkx6.1 cooperate to induce closely related zinc-finger transcription factors GATA2 and GATA3. Preceding the induction of 5-HT neurons, GATA2 activates both *Lmx1b* and *Pet1* consistent with the timing of their expression in vivo [17,18,20]. Ultimately, *Pet1* contributes to serotonergic differentiation since mice lacking *Pet1* shows a loss of 70%–80% of 5-HT neurons in the CNS [16], whereas *Lmx1b* knockout mice lack all central 5-HT neurons [14,16,17]. In addition, both *Lmx1b* and *Pet1* have been shown to be necessary and sufficient to specify 5-HT transmitter phenotype when overexpressed in the chick ventral spinal cord [18]. Whether *Lmx1b* and *Pet1* act strictly in parallel to specify 5-HT neurotransmitter phenotype [18], or whether *Pet1* is also a target gene of *Lmx1b* [17] is still unclear. During development,

expression of *Lmx1b* precedes that of *Pet1*. Moreover, *Pet1* expression is lost in *Lmx1b* knockout mice, raising the possibility that the maintenance of *Pet1* expression is dependent on *Lmx1b* [17,18]. Whether this reflects a loss of 5-HT neurons or gene regulation by *Lmx1b* remained unclear. Interestingly, the study of conditional deletion of *Lmx1b* at e12.5 showed that initiation of *Pet1* expression is independent from *Lmx1b* [18], but maintenance of its expression requires *Lmx1b* [19]. Therefore, our observation that *Pet1* expression is moderately increased in neurons overexpressing *hLmx1b* suggests that *Pet1* is responsive to *Lmx1b* induction, and that *Lmx1b* reinforces the transcriptional activity of *Pet1* [17,18].

The development of 5-HT neurons depends critically on FGF8 generated at the midbrain-hindbrain boundary and on FGF4 produced by the primitive streak. In vivo, FGF4 inhibits the development of midbrain DA neurons and promotes the development of 5-HT neurons [11]. In mES cell-derived NPs treated with 4'OHT to activate *Lmx1b* expression, addition of Shh, FGF4, and FGF8 has no effect on the yield of serotonergic differentiation compared to a sister culture treated with Shh alone. Thus, when *Lmx1b* is overexpressed, FGF8 and FGF4 become dispensable for serotonergic differentiation. This finding suggests that activation of *Lmx1b* expression is the main consequence of FGF8 and FGF4 induction in the developing NPs acquiring a 5-HT phenotype.

Our experiments show that overexpression of *Lmx1b*, either alone or in combination with Shh, has little or no effect on the yield of DA neuron differentiation. This is in accordance with a previous report [35] showing that transduction of mouse and hES cells with *Lmx1b* does not induce maturation to the midbrain DA neuron phenotype unless *Nurr1* is co-transduced in the same cell. Noteworthy, addition of FGF8 and FGF4 slightly reduced expression of midbrain DA neuron markers in accordance with the function of FGF4 in vivo [11].

To summarize, our results underline the need for proper extrinsic signals combined with intrinsic clues when engineering and manipulating ES cells for differentiation purposes. The vectors and cell lines described might be of great value for studying the gene function in serotonergic neuron development and disease pathology and in trying to understand how drugs that affect the serotonergic system alter neurotransmitter release.

## Acknowledgments

This work was supported by research grants from the European Union 6th Framework Program (FunGenES, contract No. LSHG-CT-2003-503494), INSERM AVENIR program, Région Rhône-Alpes (Cluster Handicap, Vieillessement, Neuroscience), Fondation Bettencourt-Schueller, European Science Foundation, FuncDyn Program, and Fondation CERA.

## Author Disclosure Statement

No competing financial interests exist.

## References

- Smith AG. (2001). Embryo-derived stem cells: of mice and men. *Annu Rev Cell Dev Biol* 17:435–462.
- Lee SH, N Lumelsky, L Studer, JM Auerbach and RD McKay. (2000). Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. *Nat Biotechnol* 18:675–679.
- Barberi T, P Klivenyi, NY Calingasan, H Lee, H Kawamata, K Loonam, AL Perrier, J Bruses, ME Rubio, N Topf, V Tabar, NL Harrison, MF Beal, MA Moore and L Studer. (2003). Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. *Nat Biotechnol* 21:1200–1207.
- Salli U, AP Reddy, N Salli, NZ Lu, HC Kuo, FK Pau, DP Wolf and CL Bethea. (2004). Serotonin neurons derived from rhesus monkey embryonic stem cells: similarities to CNS serotonin neurons. *Exp Neurol* 188:351–364.
- Alenina N, S Bashammakh and M Bader. (2006). Specification and differentiation of serotonergic neurons. *Stem Cell Rev* 2:5–10.
- Kumar M, SK Kaushalya, P Gressens, S Maiti and S Mani. (2009). Optimized derivation and functional characterization of 5-HT neurons from human embryonic stem cells. *Stem Cells Dev* 18:615–627.
- Tokuyama Y, SL Ingram, JS Woodward and CL Bethea. (2010). Functional characterization of rhesus embryonic stem cell-derived serotonin neurons. *Exp Biol Med (Maywood)* 235:649–657.
- Millet S, K Campbell, DJ Epstein, K Losos, E Harris and AL Joyner. (1999). A role for *Gbx2* in repression of *Otx2* and positioning the mid/hindbrain organizer. *Nature* 401:161–164.
- Joyner AL, A Liu and S Millet. (2000). *Otx2*, *Gbx2* and *Fgf8* interact to position and maintain a mid-hindbrain organizer. *Curr Opin Cell Biol* 12:736–741.
- Brodski C, DM Weisenhorn, M Signore, I Sillaber, M Oesterheld, V Broccoli, D Acampora, A Simeone and W Wurst. (2003). Location and size of dopaminergic and serotonergic cell populations are controlled by the position of the midbrain-hindbrain organizer. *J Neurosci* 23:4199–4207.
- Ye W, K Shimamura, JL Rubenstein, MA Hynes and A Rosenthal. (1998). FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. *Cell* 93:755–766.
- Ye W, M Bouchard, D Stone, X Liu, F Vella, J Lee, H Nakamura, SL Ang, M Busslinger and A Rosenthal. (2001). Distinct regulators control the expression of the mid-hindbrain organizer signal FGF8. *Nat Neurosci* 4:1175–1181.
- Pattyn A, N Simplicio, JH van Doorninck, C Goriadis, F Guillemot and JF Brunet. (2004). *Ascl1/Mash1* is required for the development of central serotonergic neurons. *Nat Neurosci* 7:589–595.
- Hendricks T, N Francis, D Fyodorov and ES Deneris. (1999). The ETS domain factor *Pet-1* is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes. *J Neurosci* 19:10348–10356.
- van Doorninck JH, J van Der Wees, A Karis, E Goedknegt, JD Engel, M Coesmans, M Rutteman, F Grosveld and CI De Zeeuw. (1999). *GATA-3* is involved in the development of serotonergic neurons in the caudal raphe nuclei. *J Neurosci* 19:RC12.
- Hendricks TJ, DV Fyodorov, LJ Wegman, NB Lelutiu, EA Pehek, B Yamamoto, J Silver, EJ Weeber, JD Sweatt and ES Deneris. (2003). *Pet-1* ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. *Neuron* 37:233–247.
- Ding YQ, U Marklund, W Yuan, J Yin, L Wegman, J Ericson, E Deneris, RL Johnson and ZF Chen. (2003). *Lmx1b* is essential for the development of serotonergic neurons. *Nat Neurosci* 6:933–938.

18. Cheng L, CL Chen, P Luo, M Tan, M Qiu, R Johnson and Q Ma. (2003). Lmx1b, Pet-1, and Nkx2.2 coordinately specify serotonergic neurotransmitter phenotype. *J Neurosci* 23:9961–9967.
19. Zhao ZQ, M Scott, S Chiechio, JS Wang, KJ Renner, RWt Gereau, RL Johnson, ES Deneris and ZF Chen. (2006). Lmx1b is required for maintenance of central serotonergic neurons and mice lacking central serotonergic system exhibit normal locomotor activity. *J Neurosci* 26:12781–12788.
20. Craven SE, KC Lim, W Ye, JD Engel, F de Sauvage and A Rosenthal. (2004). Gata2 specifies serotonergic neurons downstream of sonic hedgehog. *Development* 131:1165–1173.
21. Smidt MP, CH Asbreuk, JJ Cox, H Chen, RL Johnson and JP Burbach. (2000). A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. *Nat Neurosci* 3:337–341.
22. Kim JH, JM Auerbach, JA Rodriguez-Gomez, I Velasco, D Gavin, N Lumelsky, SH Lee, J Nguyen, R Sanchez-Pernaute, K Bankiewicz and R McKay. (2002). Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. *Nature* 418:50–56.
23. Reubinoff BE, MF Pera, CY Fong, A Trounson and A Bongso. (2000). Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. *Nat Biotechnol* 18:399–404.
24. Ben-Hur T, M Idelson, H Khaner, M Pera, E Reinhartz, A Itzik and BE Reubinoff. (2004). Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. *Stem Cells* 22:1246–1255.
25. Feil R, J Wagner, D Metzger and P Chambon. (1997). Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. *Biochem Biophys Res Commun* 237:752–757.
26. Mangeot PE, D Negre, B Dubois, AJ Winter, P Leissner, M Mehtali, D Kaiserlian, FL Cosset and JL Darlix. (2000). Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. *J Virol* 74:8307–8315.
27. Wianny F, A Bernat, G Marcy, C Huissoud, S Markossian, V Levieil, H Kennedy, P Savatier and C Dehay. (2008). Derivation and cloning of a novel Rhesus ES cell line stably expressing tau-GFP. *Stem Cells* 26:1444–1453.
28. Suter DM, L Cartier, E Bettiol, D Tirefort, ME Jaconi, M Dubois-Dauphin and KH Krause. (2006). Rapid generation of stable transgenic embryonic stem cell lines using modular lentivectors. *Stem Cells* 24:615–623.
29. Vallier L, J Mancip, S Markossian, A Lukaszewicz, C Dehay, D Metzger, P Chambon, J Samarut and P Savatier. (2001). An efficient system for conditional gene expression in embryonic stem cells and in their in vitro and in vivo differentiated derivatives. *Proc Natl Acad Sci U S A* 98:2467–2472.
30. Srinivas S, T Watanabe, CS Lin, CM Williams, Y Tanabe, TM Jessell and F Costantini. (2001). Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev Biol* 1:4.
31. Wiles MV and BM Johansson. (1999). Embryonic stem cell development in a chemically defined medium. *Exp Cell Res* 247:241–248.
32. Tropepe V, S Hitoshi, C Sirard, TW Mak, J Rossant and D van der Kooy. (2001). Direct neural fate specification from embryonic stem cells: a primitive mammalian neural stem cell stage acquired through a default mechanism. *Neuron* 30:65–78.
33. Negre D, PE Mangeot, G Duisit, S Blanchard, PO Vidalain, P Leissner, AJ Winter, C Roubourdin-Combe, M Mehtali, P Moullier, JL Darlix and FL Cosset. (2000). Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. *Gene Ther* 7:1613–1623.
34. Dull T, R Zufferey, M Kelly, RJ Mandel, M Nguyen, D Trono and L Naldini. (1998). A third-generation lentivirus vector with a conditional packaging system. *J Virol* 72:8463–8471.
35. Martinat C, JJ Bacci, T Leete, J Kim, WB Vanti, AH Newman, JH Cha, U Gether, H Wang and A Abeliovich. (2006). Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. *Proc Natl Acad Sci U S A* 103:2874–2879.

Address correspondence to:

*Dr. Pierre Savatier*

*INSERM U846*

*18 Avenue Doyen Lépine*

*69500 Bron*

*France*

*E-mail: pierre.savatier@inserm.fr*

*Dr. Agnieszka Bernat*

*INSERM U846*

*18 Avenue Doyen Lépine*

*69500 Bron*

*France*

*E-mail: agnieszka.bernat@inserm.fr*

Received for publication June 8, 2010

Accepted after revision July 22, 2010

Prepublished on Liebert Instant Online July 22, 2010

